Since brain cancer affects a relatively small portion of the population, David and his team work in the early stages of the discovery and development pipeline in order to “buy down the risk” to speed progress of innovative new treatments to the clinic. David manages the organization’s academic research grants and leads ABC2’s seed investment fund, which has backed companies such as Regulus Therapeutics, Agios Pharmaceuticals and Tocagen. He is currently working to launch a startup scientific and social enterprise to advance genomic analysis for cancer patients. With his corporate, government and non-profit management background, David is adept at forging collaborative partnerships between researchers from academia, government and bio-pharmaceutical companies.
Prior to joining ABC2, David served as Executive Director of the National Conference on Citizenship (NCoC), a Washington think tank chartered by Congress to enhance civic participation. While at NCoC, David and his team launched the Civic Health Index, a comprehensive annual report that tracks social impact across the country. David has a deep understanding of public policy issues ranging from education to healthcare to entrepreneurship. David began his career at Xerox Corporation identifying strategic opportunities and providing market assessments in the office of CEO David Kearns. He also served as an Advisor to the Startup America Partnership - a White House initiative launched to celebrate, inspire, and accelerate high-growth entrepreneurship throughout America.
David graduated with honors from Colby College and was a Hansard Scholar at the London School of Economics.